Next
The board of directors of AMS BioteQ (TPE:6864) approved the appointment of Deputy General Manager Zhang Yiwei.
WHAT'S NEW
MEDIA
2024-09-03
Seizing the overseas dressing market, AMS BioteQ obtains its first distribution contract in Japan.
AMS BioteQ , stock code: (6864-TW)) announced on August 30 that it has signed a distribution contract for its innovative medical material 'SIPSIP Foam Wound Dressing' with a group of medical institutions in Japan, securing its first overseas order. This marks its official entry into the Japanese market, aiming to seize business opportunities and serve as a foothold for expanding into international chronic wound care.
Innovative Medical Care Material ''SIPSIP Foam Wound Dressing''
AMS BioteQ (6864-TW) debuted its ''SIPSIP Foam Wound Dressing'' at the Medical Japan international medical exhibition in October 2023, receiving expressions of interest for collaboration from multiple parties. The product officially obtained PMDA medical device approval in Japan in July 2024. Even before securing this approval, several Japanese distributors had inquired and engaged in discussions regarding agency cooperation. The successful distributor signed this time is a group of medical institutions in the Kanto region, which includes several nursing homes and long-term care centers, boasting rich market resources and distribution channels.
AMS BioteQ emphasizes that it plans to launch more advanced innovative medical materials in the future, such as SIPSIP Pro and SIPSIP Combo, which are hydrophilic dressings. Their main highlights include patented wound regeneration technology, a unique dressing physical structure, non-allergenic properties, and high water absorption. Animal experiments using mouse wound models have confirmed their effectiveness in promoting wound healing and functional tissue regeneration, especially for difficult and deep wounds. This breakthrough innovative medical technology can be applied to develop various wound care products, expanding the company's product line and exploring different medical market opportunities.
AMS BioteQ (6864-TW) has entered its sixth year since its establishment, successfully creating a dual-track approach of drug research and self-developed dressings, providing a more diverse range of options for patients and healthcare providers.
Founder and Chairman Tsai Yi-ju stated that signing the distribution contract with Japan is an important step in the company's internationalization strategy and a full recognition of the quality of its products and market opportunities. This collaboration will further enhance the company's visibility and influence in the international market and promote its long-term development.
Chairman Tsai emphasized that AMS BioteQ has now entered its sixth year, successfully establishing a dual approach of drug research and self-developed dressings to offer more diverse choices for patients and healthcare providers. In the future, the company will continue to invest in the development of different indications, aiming to become a leading brand in the innovative medical market through expanding its international presence and technological influence.